Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant sorafenib in operable renal cell cancer
NL-OMON26901Not yet recruiting
- Sponsor
- Amsterdam UMC
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sorafenib in renal cell carcinoma (RCC), sponsored by Amsterdam UMC. Primary endpoints: Tumor reduction by CT and Quantitative perfusion change. Planned start Mar 2006; status: not yet recruiting.
02
Drugs
sorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON26901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26901.